Moderna (MRNA)
(Delayed Data from NSDQ)
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
Zacks News
Should You Buy Oil & Gas ETFs Now?
by Neena Mishra
Energy ETFs rebounded strongly in November but are still down significantly for the year
Productivity Increases in Q3
by Zacks Equity Research
Productivity Increases in Q3
Moderna (MRNA) to Supply More Doses of COVID-19 Vaccine to Canada
by Zacks Equity Research
Moderna (MRNA) announces deal to supply 20 million additional doses of its COVID-19 vaccine candidate, mRNA-1273, to the Canadian Government, upon potential approval. The total tally is now 40 million doses.
Markets Find Vaccine-Rally Equilibrium; AZO Mixed in Q1
by Mark Vickery
Great Britain injects its first Pfizer (PFE)-BioNTech (BNTX) vaccine patients today, marking a momentous occasion whereby the world may soon return to pre-pandemic activities.
Small-Cap ETFs Face Off: IWM Vs. IJR
by Sweta Killa
Small-cap companies are closely tied to the U.S. economy and are thus poised to outperform when the economy improves.
Pfizer (PFE) Up 14% in 3 Months on COVID-19 Vaccine Progress
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is now approved for emergency use in United Kingdom and Bahrain.
Markets Close Mixed; Toll Brothers (TOL) Puts Up Record Quarter
by Mark Vickery
It's the hottest home market Toll Brothers has seen in 30 years, with net signed contracts +68% -- an all-time high for any quarter in the company's history.
Can Restaurant Stocks Move Higher?
by Sejuti Banerjea
Restaurant companies have been done a lot of innovating this year and they should do much better next year as pandemic concerns wane.
The Zacks Analyst Blog Highlights: Cisco Systems, CVS Health, Moderna, Pfizer and Hilton Worldwide
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco Systems, CVS Health, Moderna, Pfizer and Hilton Worldwide
Markets Hit Record Highs, Promise Further Growth: 5 Top Picks
by Zacks Equity Research
Promising vaccine news and hopes of further fiscal stimulus helped benchmark indexes to close at record highs, making this a prudent time to invest in names like Cabot (CBT) and Forestar (FOR)
Holiday Shopping Shifts to E-Commerce: ETFs to Tap
by Sweta Killa
Given the digital shopping boom, stocks in the Internet and e-commerce retail space look poised for solid gains this holiday season.
3 Growth Stocks to Tap the COVID-Driven Shift in MedTech
by Urmimala Biswas
To beat the pandemic blues and maximize capital gains, investors can now scoop up these fundamentally-strong MedTech growth stocks.
Top Analyst Reports for Cisco, CVS Health & Moderna
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), CVS Health Corporation (CVS) and Moderna, Inc. (MRNA).
The Vaccines Are Here. Are We Out of the Woods Now?
by John Blank
It almost seems like we are just an appointment at the doctor's office away from opening up our economy again.
Stocks to Track in December as Markets Peak
by Sweta Killa
December is likely to be filled with events or stock/sector specific news that could provide a boost to the stocks.
Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More
by Zacks Equity Research
Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.
After a Historic November, What Awaits ETFs in December?
by Sweta Killa
Let's delve into some of the major events of December and learn how to tap the opportune moments with ETFs.
Pfizer/BioNTech's COVID-19 Vaccine Gets Approval in U.K.
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate becomes the first-ever vaccine to get authorization.
Encouraging News on COVID-19 Vaccine
by Zacks Equity Research
Encouraging News on COVID-19 Vaccine
ADP Reports 307K New Jobs, Revisions Up
by Mark Vickery
307K new private-sector jobs was lower than expected, and beneath the upwardly revised 404K from October.
5 International ETFs That Outstripped US Market in November
by Sweta Killa
November was a banner month for the global stock market despite the rising number of COVID-19 cases.
Cimarex Energy (XEC) Up 48.6% QTD: What's Behind the Rally?
by Zacks Equity Research
Improving oil prices on positive coronavirus vaccine results aid Cimarex (XEC).
Stock Market News for Dec 2, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Tuesday on the back of optimism surrounding COVID-19 vaccine.
Pfizer/BioNTech Seek Marketing Nod for COVID-19 Vaccine in EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.
Will Americans Get COVID-19 Vaccine Sooner Than Europeans?
by Kinjel Shah
Moderna (MRNA), and Pfizer (PFE)/BioNTech (BNTX) file for emergency use authorization of their COVID-19 vaccine candidates in Europe